CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 11, 2013

Primary Completion Date

August 7, 2017

Study Completion Date

August 7, 2017

Conditions
Advanced CancersLeukemia
Interventions
PROCEDURE

Leukapheresis

Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.

DRUG

Fludarabine

25 mg/m2 by vein on Days -5 to Day -3.

DRUG

Cyclophosphamide

250 mg/kg by vein on Days -5 to -3.

PROCEDURE

T-cell Infusion

Beginning dose of genetically modified cells is \> 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01653717 - CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter